Poziotinib showed meaningful activity in heavily treated HER2-positive breast cancer cases22 and neratinib could be effective as third-line treatment compared with lapatinib (NALA trial, http://www.pumabiotechnology.com/pr20181217.html). Here, ERBB2 is linked to breast carcinoma.